Outcomes of antiretroviral treatment programs in rural Southern Africa by Wandeler, Gilles et al.
Outcomes of antiretroviral treatment programs in rural Southern
Africa
Gilles Wandeler, MD, MSc1,2, Olivia Keiser, PhD1, Karolin Pfeiffer, MD MPH3, Sabrina
Pestilli, MD, MPH3, Christiane Fritz, MD3, Niklaus D. Labhardt, MD, MIH3, Franzisco
Mbofana, MD, MPH4, Robert Mudyiradima, MD, MPH5, Jan Emmel, MPH3, Matthias Egger,
MD, MSc1, and Jochen Ehmer, MD, MA3 for the SolidarMed ART program and IeDEA-
Southern Africa
1Division of International and Environmental Health, Institute of Social and Preventive Medicine
(ISPM), University of Bern, Bern, Switzerland 2Infectious Diseases Clinic, Bern University
Hospital, Bern, Switzerland 3SolidarMed, Lucerne, Switzerland 4Ministry of Health, Mozambique
5Ministry of Health, Zimbabwe
Abstract
Background—Data on outcomes of antiretroviral treatment (ART) programs in rural sub-
Saharan African are scarce. We describe early losses and long-term outcomes in six rural
programs in Southern Africa with limited access to viral load monitoring and second-line ART.
Methods—Patients aged ≥16 years starting ART in two programs each in Zimbabwe,
Mozambique and Lesotho were included. We evaluated risk factors for no follow-up after starting
ART and mortality and loss to follow-up (LTFU) over 3 years of ART, using logistic regression
and competing risk models. Odds ratios and sub-distribution hazard ratios, adjusted for gender,
age category, CD4 category and WHO stage at start of ART are reported.
Results—Among 7,725 patients, 449 (5.8%) did not return after initiation of ART. Over 9,575
person-years, 698 (9.6%) of those with at least one follow-up visit died and 1,319 (18.1%) were
LTFU. At 3 years the cumulative incidence of death and LTFU were 12.5% (11.5–13.5%) and
25.4% (24.0–26.9%), respectively, with important differences between countries: in Zimbabwe
75.1% (72.8–77.3%) were alive and on ART at 3 years compared to 55.4% (52.8–58.0%) in
Lesotho and 51.6% (48.0–55.2%) in Mozambique. In all settings young age and male gender
predicted LTFU, whereas advanced clinical stage and low baseline CD4 counts predicted death.
Conclusions—In African ART programs with limited access to second-line treatment, mortality
and LTFU are high in the first 3 years of ART. Low retention in care is a major threat to the
sustainability of ART delivery in Southern Africa, particularly in rural sites.
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INTRODUCTION
The World Health Organization (WHO) estimates that over 5 million HIV-1 infected people
were receiving antiretroviral therapy (ART) in low- and middle-income countries by the end
of 20091. However, high mortality and loss of patients to follow-up in the context of the
rapid scale-up of ART and weak health systems challenge clinical and programmatic
outcomes in low-income settings in Africa.2, 3 In recent years an increasing body of
evidence, including two systematic reviews, has shown low retention in care of patients
starting ART in sub-Saharan Africa.4–7 Early losses after the initiation of ART have been
recognized as important barriers to the success of ART programs in resource-constrained
settings. 8, 9 According to a recent report based on aggregate data from national programs,
retention in care in countries in sub-Saharan Africa is estimated to be as low as 75.2% at 12
months, possibly due to high early mortality.10
Data on short-term and long-term clinical and programmatic outcomes in rural sub-Saharan
Africa, especially in settings with limited diagnostic possibilities, access to viral load testing
and second-line ART, are scarce. Due to many structural factors influencing the scale-up of
ART, the distribution of services may be inequitable between rural and urban African
settings.11 For instance, the impact of the chronic shortage of health care workers has been
most devastating in rural settings.12
Mozambique, Zimbabwe and Lesotho are three countries with a high prevalence of HIV
infection where ART delivery has been scaled up in the last few years. Despite the
substantial increase in patients starting ART, only 30%, 34% and 48% of the HIV-infected
population in need of treatment in Mozambique, Zimbabwe and Lesotho, respectively, were
estimated to have access to ART by 2009.1 In this context, SolidarMed, a Swiss Non-
Governmental Organization (NGO), established the SolidarMed ART (SMART) program in
2005,13 with a focus on supporting the delivery of ART and health care in rural settings in
sub-Saharan Africa. We examined the importance of no follow-up after initiation of ART as
well as mortality and loss to follow-up (LTFU) over three years of ART in the SMART
programs in Zimbabwe, Mozambique and Lesotho.
METHODS
SolidarMed AntiRetroviral Treatment (SMART) program
The SMART program was launched in rural Zimbabwe, Mozambique and Lesotho in 2005
to support the national ART programs by introducing voluntary testing and counseling
(VCT) services, antiretroviral drugs for the prevention of mother-to-child transmission
(PMTCT) of HIV, and by providing ART and treatments of opportunistic diseases. While
national authorities and health systems continued to manage services, SolidarMed facilitated
implementation, bridged gaps in funding and supported capacity building and monitoring.
Subsequently the program was expanded to 9 district health facilities and over 40 affiliated
peripheral health centers in Lesotho (3 districts), Zimbabwe (2 districts), Mozambique (2
districts) and Tanzania (2 districts).
All ART programs included in this study are rural. Sixty percent of patients in Lesotho and
90% of those in Mozambique and Zimbabwe were subsistence farmers and 80% were
illiterate. Every ART program has a well defined catchment area, which includes between
55,000 people in Lesotho and 240,000 in Mozambique. Programs are nurse-led, with only 2
medical doctors in Mozambique, 4 in Lesotho and 5 in Zimbabwe, and there is usually only
one functioning ambulance per area. Finally, most patients travel between 1 and 3 hours to
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the clinic and distances to the next referral clinic can be up to 240 kilometers, depending on
the area.
The programs in Zimbabwe, Mozambique and Lesotho are part of the International
epidemiologic Databases to Evaluate AIDS in Southern Africa (IeDEA-SA), a collaboration
of ART programs from seven countries in the region. The IeDEA networks in sub-Saharan
Africa have been described in detail elsewhere.14 In the present study we analyzed data from
the SMART programs in Zimbabwe, Mozambique and Lesotho.
Data collection
SolidarMed supports the monitoring of ART programs through the provision and
maintenance of a purpose-built clinical database. Data entry clerks are trained by senior
local data managers. Data are prospectively recorded on standardized national patient forms
by clinical nurses and entered by data clerks into the database, which is the same at all sites.
Data collection starts on the day ART is initiated and continues at each visit to the clinic.
Information on demographic characteristics such as date of birth, marital status, occupation,
residency as well as past medical history, including year of diagnosis of HIV infection and
prior CD4 counts is recorded on the first day. Clinical parameters, including height, weight,
opportunistic infections and WHO stage and laboratory parameters are recorded at baseline
and during follow-up. Treatment adherence is monitored by two means: pill counts and
adherence to medical appointments.
Local data supervisors regularly perform random quality checks on site, comparing entered
data with paper forms. Twice a year, an additional quality-check is performed with the help
of staff at SolidarMed head-quarters in Lucerne, Switzerland and the Institute of Social and
Preventive Medicine (ISPM) at the University of Bern, Switzerland. Personal identifiers are
removed before transfer of the data for statistical analysis. The present analysis includes all
data available up to the end of June 2010.
Counseling, follow-up and tracing of patients
Three individual or group adherence counseling sessions are normally held before the
initiation of ART and further adherence counseling takes place during ART, if required.
Most patients are seen by nurses and follow-up visits are scheduled according to national
algorithms, generally every month. All new clinical events, such as pregnancy and
opportunistic infections are recorded whenever patients seek medical care. CD4 counts are
determined every 3 to 6 months, depending on the clinic. Further laboratory examinations
include hemoglobin, total white cell count, total lymphocyte count, platelets, alanine
transaminase (ALAT) and creatinine (only in Lesotho). All changes to the antiretroviral
treatment regimens, serious adverse effects and the prescription of prophylactic treatments
are recorded. There are no death registries in the countries involved and ascertainment of
deaths occurring outside health facilities therefore relies on reports from outreach workers or
direct information by families, friends or local authorities. Whenever patients have missed
their last appointment at the treatment site, they are traced through home visits by nurses,
volunteers, lay counselors or community associations.
Inclusion criteria and outcomes
All patients aged 16 years or older with complete data on sex and date of birth who started
ART consisting of at least 3 drugs between January 2005 and June 2010 were included in
the analysis. We examined three outcomes: no follow-up after starting ART, LTFU and
death. LTFU was defined as not returning to the facility for 6 months or longer. Patients
who started ART within the last 6 months before the closing date of this analysis were
therefore excluded from this study. Follow-up of patients transferred to another clinic was
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censored at the date of their last visit. Retention in care was defined as alive on ART and in
active follow-up over the study period.
Statistical analyses
We identified risk factors for no follow-up after starting ART using logistic regression.
Variables at the start of ART included in the model were sex, age (16–29, 30–39, 40 years
and over), CD4 cell count (0–49, 50–99, 100–199, 200 cells/μL and over), WHO stage (I/II
or III/IV), calendar year (before 2008, 2008 and after 2008), country and initial treatment
regimen (Nevirapine- or Efavirenz-based).
We used logistic regression to identify factors associated with not returning to the clinic
after initiation of ART, and competing risk models to analyzed mortality and LTFU. Death
is a competing risk of LTFU: patients who die can no longer become lost to follow-up.
Similarly, deaths in patients who are lost to follow-up are no longer recorded in the
database. Standard time-to-event analyses, for example Kaplan-Meier curves or Cox
regression, ignore the competing risks of death and LTFU and may produce biased results.
We therefore plotted stacked competing risk cumulative incidence curves of LTFU and
mortality up to three years after starting ART.15 Furthermore, we used the competing risk
sub-distribution models described by Fine and Gray16 to examine risk factors for LTFU or
death. All statistical analyses were performed using Stata (version 11, Stata Corporation,
College Station, TX, USA).
Ethical approval
We obtained ethical approval for the collection and transfer of data from the Comité
Nacional de Bioética para a Saude, Republica de Moçambique, the Medical Research
Council of Zimbabwe and the Ministry of Health and Social Welfare of Lesotho for the
SMART programs in Mozambique, Zimbabwe and Lesotho, respectively. In the case of
Lesotho, the ethical clearance was issued to SolidarMed and its main partner, the Christian
Health Association of Lesotho (CHAL). In Mozambique, the ethics committee required
individual informed consent, whereas informed consent was not required in Zimbabwe or
Lesotho.
RESULTS
Characteristics of clinics and patients
The six ART programs differed in terms of the number of nurses, medical officers and
doctors seeing patients, travel times of patients, and first-line regimens used (Table 1).
Staffing was lowest in Mozambique, where only around 20 nurses and 1 or 2 medical
doctors were available per 100,000 population. The mean travel time to the clinic ranged
from 1 hour in Zaka, Zimbabwe, to 3 hours in Ancuabe, Mozambique. All sites except
Ancuabe had flow cytometry to count CD4 cells on site but no facility had direct access to
viral load monitoring. A fixed-dose combination of stavudine (d4T), lamivudine (3TC) and
nevirapine (NVP) was the most prescribed ART regimen during the study period. In
Lesotho, zidovudine (ZDV) or tenofovir (TDF) were used increasingly in first-line ART in
recent years. Over 90% of patients were treated with a NVP-based regimen and only 3
different ART regimens were used to treat more than 95% of patients in Mozambique and
Zimbabwe. In Lesotho over half of patients received an Efavirenz (EFV)-based initial
regimen and the number of treatment options was higher due to the increasing availability of
TDF. During the study period, protease inhibitors were not available or not used, depending
on the site.
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A total of 9,271 patients started ART during the study period. We excluded patients with
incomplete data on sex or age (n=26), as well as patients who started ART less than 6
months before the closing date of the database (n=1,520): 7,725 patients were therefore
included in analyses. In all clinics the majority of patients were women; overall 5,018 (65%)
were female (Table 2). Patients in Mozambique were younger than those starting ART in the
two other countries. Median CD4 cell counts at start of ART ranged from 91 cells/μL in
Zaka, Zimbabwe, to 279 cells/μL in Ancuabe, Mozambique. The proportion of patients in
advanced clinical stage (WHO stage III/IV) was high in all clinics ranging from 48.3% in
Seboche, Lesotho, to 94.8% in Chiure, Mozambique.
Patients with no follow-up after starting ART
Overall 449 patients (5.8%) were not seen after the ART initiation visit, with large
variations between countries (Table 1). In Mozambique, 21.8% of patients who started ART
in Ancuabe and 8.9% of patients from Chiure did not return, whereas in Zimbabwe and
Lesotho, the proportion of patients with no follow-up was below 5%. Younger age and, to a
lesser extent, male gender were associated with the probability of no follow-up (Table 3).
Patients with CD4 cell counts below 50 cells/μL or missing CD4 counts at baseline were
also more likely not to return to the health facility after the start of ART. The risk of no
follow-up was higher in Mozambique than in the two other countries. Finally, the
probability of not returning after the first visit was higher in more recent years (Table 3).
Mortality and LTFU
Over 9,575 person-years of follow-up 1,319 patients (18.1%) of the 7,276 patients with at
least one follow-up visit were LTFU and 698 patients (9.6%) died. The crude mortality rate
was 7.3 (95% CI 6.8–7.9) deaths per 100 person-years and the rate of LTFU 13.8 (13.1–
14.5) per 100 person-years. There were important differences between countries: Figure 1
shows cumulative percentages from competing risk models of patients alive and on ART,
patients lost to follow up and deaths for Zimbabwe, Lesotho and Mozambique. At 3 years,
9.0% (95% CI 7.6–10.5) were known to have died in Zimbabwe, 15.7% (13.9–17.6) were
lost to follow-up and 75.1% (72.8–77.3) were alive and on ART. The figures were less
favorable for Mozambique: 17.4% (14.9–20.0); 31.0% (27.8–34.2) and 51.6% (48.0–55.2),
respectively, with Lesotho in an intermediate position (Figure 1).
Male gender, advanced clinical stage and CD4 cell counts below 50/μL at ART initiation
were consistently associated with higher mortality (Table 3). Older patients and females
were less likely to be LTFU over the 3 years after starting ART, whereas the risk of LTFU
was highest in patients without a CD4 cell count at the start of ART and if treatment was
initiated after 2007, compared to the other groups. Patients in Zimbabwe were less likely to
be lost to follow-up than those treated in Lesotho or Mozambique.
DISCUSSION
In this study of six ART programs in rural Mozambique, Zimbabwe and Lesotho, we found
that the proportion of patients with no follow-up after starting ART differed from one setting
to the other, reaching over 20% in the most remote setting in Mozambique. Retention in care
over the first 3 years after the initiation of ART was unsatisfactory in all settings. Among
patients followed up after the initial visit, mortality and loss to follow-up were particularly
high in young men, and higher in Mozambique than in the other two countries.
The SolidarMed ART program serves poor, rural populations, in settings with little
employment, low literacy and fragile, understaffed health systems. Indeed, one explanation
for the poor retention is the limited capacity of the regional health systems, which were
Wandeler et al. Page 5
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2013 February 1.
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
overwhelmed by the rapid scale-up of ART.8 This is illustrated by the two facilities in
Mozambique: in Chiure, staff was carefully trained and pre-ART counseling consistently
implemented. These efforts generally translated into stable treatment partnerships. In
contrast, the delivery of ART in Ancuabe started later and grew faster, initially without
external support, and the training of staff was limited. Pre-ART counseling was not
standardized and often not performed, leading to the initiation of treatment in patients who
were ill prepared to take on the challenges of life-long ART. Structural factors, as well as
socio-cultural factors have previously been linked to poor outcomes in ART programs. 17–19
Patients who do not come back to the health care facility after starting ART reflect a
particular type of program failure. In our study over 5% of patients did not return after their
first visit. Brinkhof et al. found somewhat lower rates of early loss in the African programs
included in the ART-LINC collaboration; however, they mainly studied urban programs.8
Long-term retention was also low in our study, and particularly low in Lesotho and
Mozambique where only 55% and 52% of patients, respectively, were alive and on ART at 3
years, fewer than the 72% estimated in the systematic review and meta-analysis of Fox et
al.5 Again, most of the programs included in this review were from urban centers. A study of
the barriers to accessing ART in Mozambique found that availability and cost of transport as
well as clinic fees were major issues, particularly in rural areas, where the distance to the
nearest clinic is large, public transport limited and unemployment high.20 In Lesotho,
retention in care was below the estimates previously reported by Médecins sans Frontières in
another setting in Lesotho. One explanation for this might be the large proportion of migrant
workers to neighboring South Africa, a sub-population known to be at higher risk of LTFU
than the general population.21, 22
Patients lost to follow-up might reflect unaccounted self-referrals to other sites23, but this is
unlikely in rural Mozambique and Zimbabwe, where ART is not widely available. In
Lesotho, patients are routinely referred to peripheral health centers when clinically stable,
but these patients will continue to be included in the common database. Men and patients
under 30 years of age were more likely to be LTFU. Low retention in care of these groups is
an important finding of our study and is consistent with other reports from Western, Eastern
and Southern Africa.7, 8, 24, 25 Because patients in this age group are more likely to have no
follow-up, be LTFU or to die than older patients, they warrant special attention and support
from ART programs, both in urban and rural settings. The increasing proportion of patients
lost to follow-up in recent years must be of concern. Even though it is difficult to attribute
these changes to specific factors, the increasing number of patients needing treatment in
each ART program in the context of weak health systems with poor organizational and
logistic capacities probably had a major impact on the retention in care of patients on ART.
The levels of staffing were extremely low in many of these health care facilities,
contributing to the high proportions of patients lost or without any follow-up after the
initiation of ART.
In the presence of LTFU the mortality observed among patients remaining in care may
substantially under-estimate mortality in all patients starting ART because mortality in
patients LTFU tends to be high. Several methods have been used to address this issue,
including statistical modeling based on mortality in patients traced in Kenya, and linkage of
HIV cohort records with the national death registry in South Africa.26–29 A nomogram and
web calculator (implemented at www.iedea-sa.org) has also been developed, based on the
fact that mortality of all patients starting ART is a weighted average of mortality among
patients LTFU and patients remaining in care. When entering plausible estimates of
mortality in patients LTFU from a meta-analysis30 we found mortality at one year increased
to about 11% (from 6%) in Zimbabwe, to about 15% (from 8%) in Lesotho and to about
19% (from 12%) in Mozambique.
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The lack of access to viral load monitoring and second-line ART may have contributed to
the high mortality. When comparing outcomes of ART in South Africa, where viral load
monitoring is routine, with Malawi and Zambia, where monitoring is based on CD4 cell
counts, we recently found that at 3 years more patients were on a failing first-line regimen,
fewer patients had switched to second-line ART and mortality was higher in Malawi and
Zambia than in South Africa.31 These observational data are in contrast with the results from
a randomized clinical trial 32 and a mathematical modeling study33, which showed no or
little association between viral load monitoring and mortality. As none of the health
facilities included in the present study had access to viral load monitoring, it was not
possible to assess the potential effect of different monitoring strategies on ART outcomes
directly in our study. Finally, mortality was higher in men and in those with CD4 cell counts
below 50/μL and advanced clinical stage, in line with the results of a prognostic model of
patients starting ART in sub-Saharan Africa.34
There are several limitations to our study. First, the mortality we observed in patients
remaining in care is bound to be an underestimate of mortality at the level of the program.
Unfortunately, the limited resources mean that patients LTFU cannot be consistently traced
by outreach teams. We could therefore not provide accurate information on program-level
mortality, but estimated overall mortality based on published data on mortality in patients
LTFU in sub-Saharan Africa26, 27. We did not systematically compare outcomes of rural
programs with those located in urban areas, but such an analysis is planned within the
IeDEA collaboration. No information was available on causes of death. Laboratory
equipment was sometimes out of order or could not be operated because of power breaks or
lack of reagents, resulting in a considerable number of patients with missing CD4 counts at
baseline. This was especially true for Mozambique: the programs either did not have a CD4
count device on site (Ancuabe) or faced frequent breakdowns of the device (Chiure).
Severely ill and hospitalized patients were therefore started on ART without baseline CD4
count. Thus, the higher baseline CD4 counts in these 2 programs mainly relate to patients
who were not hospitalized and in better health. Such selection bias was less important in
Zimbabwe and Lesotho, where baseline CD4 count measurements seemed to be missing
essentially at random.
In conclusion, our study illustrates some of the challenges rural ART programs face in sub-
Saharan Africa. In particular, our results document the difficulties in retaining patients in
care after they initiate ART and must raise concerns about poor long term clinical outcomes
in settings with weak health systems and limited access to viral load monitoring and second-
line ART regimens. Approaches to improve retention in care in such settings have been
described recently, including reduction of the frequency of visits in patients who are stable,
down referral of ART and the involvement of peer support groups.12, 35, 36 Such
interventions need to be tailored to local contexts and implemented alongside health systems
strengthening initiatives37.
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Figure 1.
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